Comparison
Sermorelin vs. Tirzepatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
86168-78-7
2023788-19-2
Molecular weight
3358 g/mol
4813 g/mol
Half-life
0.2 h
116 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSRYXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSMechanism of action
Sermorelin
Synthetic analogue of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Stimulates pulsatile endogenous growth-hormone secretion from the pituitary via the GHRH receptor. Very short plasma half-life — pharmacodynamic effect lasts several hours nevertheless.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
3
of which in humans
3
3
Effects recorded
3
4
Open conflicts
1
0
Documented adverse events
3
2